Cigna Investments Inc. New decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,041 shares of the biopharmaceutical company’s stock after selling 156 shares during the period. Cigna Investments Inc. New’s holdings in Regeneron Pharmaceuticals were worth $1,494,000 as of its most recent SEC filing.
Other hedge funds also recently bought and sold shares of the company. Korea Investment CORP increased its position in Regeneron Pharmaceuticals by 223.9% in the first quarter. Korea Investment CORP now owns 298 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 206 shares during the period. FNY Managed Accounts LLC acquired a new position in Regeneron Pharmaceuticals during the first quarter valued at $140,000. Alpha Windward LLC increased its position in Regeneron Pharmaceuticals by 4.4% in the first quarter. Alpha Windward LLC now owns 383 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 16 shares during the period. IFP Advisors Inc increased its position in Regeneron Pharmaceuticals by 33.2% in the second quarter. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 96 shares during the period. Finally, Wendell David Associates Inc. acquired a new position in Regeneron Pharmaceuticals during the second quarter valued at $204,000. 67.16% of the stock is currently owned by institutional investors and hedge funds.
Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) traded up 0.85% on Friday, hitting $467.98. The stock had a trading volume of 549,722 shares. The firm has a market capitalization of $49.62 billion, a price-to-earnings ratio of 46.95 and a beta of 1.66. The company’s 50 day moving average is $489.51 and its 200-day moving average is $430.92. Regeneron Pharmaceuticals, Inc. has a 1-year low of $325.35 and a 1-year high of $543.55.
REGN has been the topic of a number of research reports. Vetr downgraded Regeneron Pharmaceuticals from a “sell” rating to a “strong sell” rating and set a $368.84 price objective on the stock. in a report on Monday, May 15th. Robert W. Baird downgraded Regeneron Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $408.00 price objective on the stock. in a report on Tuesday, August 1st. Zacks Investment Research downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 4th. Credit Suisse Group downgraded Regeneron Pharmaceuticals to a “hold” rating and set a $485.00 price objective on the stock. in a report on Friday, July 14th. Finally, Canaccord Genuity set a $522.00 price objective on Regeneron Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, July 28th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $495.59.
In other news, EVP Neil Stahl sold 8,306 shares of the company’s stock in a transaction dated Thursday, June 22nd. The shares were sold at an average price of $532.55, for a total transaction of $4,423,360.30. Following the transaction, the executive vice president now owns 43,950 shares in the company, valued at $23,405,572.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman P Roy Vagelos sold 9,295 shares of the company’s stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $458.14, for a total transaction of $4,258,411.30. Following the transaction, the chairman now owns 414,156 shares in the company, valued at approximately $189,741,429.84. The disclosure for this sale can be found here. In the last 90 days, insiders sold 84,404 shares of company stock worth $40,303,792. 10.40% of the stock is owned by company insiders.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
What are top analysts saying about Regeneron Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Regeneron Pharmaceuticals Inc. and related companies.